Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
FEMALE
Healthy Volunteers
ID06417177

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Led by University of Missouri-Columbia · Updated on 2025-09-09

75

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore how early aging and menopause affect blood vessel responses to low oxygen levels, focusing on the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women. The study is conducted by the University of Missouri-Columbia and involves healthy female volunteers aged 18 to 70 years. It is designed as an early phase 1, randomized, single-masked clinical trial. Participants will be exposed to three experimental conditions: hypoxia (breathing low oxygen air through a mask), the cold pressor test (immersing the foot in ice water), and hypercapnia (breathing high carbon dioxide air through a mask). During the study, participants will receive one of three oral treatments: propranolol at 1 mg/kg, gemtesa at 75 mg, or a placebo pill, to study their effects on vascular responses. Throughout the trial, researchers will measure changes in forearm blood flow from baseline to five minutes after exposure. Participants will undergo these tests under controlled conditions to monitor cardiovascular responses. The study includes assessments related to aging, menopause, hypoxia, and vasodilation, with continuous safety monitoring. The total participation duration aligns with the study procedures and follow-up up to the planned end date in July 2026.

CONDITIONS

Brief Title

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Who Can Participate

Age: 18Years - 70Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Female assigned at birth
  • Premenopausal, perimenopausal, or postmenopausal status
  • Healthy weight with body mass index (BMI) between 18 and 30 kg/m2
Not Eligible

You will not qualify if you...

  • Male assigned at birth
  • Pregnancy or breastfeeding
  • Use of hormone replacement therapies
  • History of hysterectomy
  • Body mass index greater than 30 kg/m2
  • Diagnosed sleep apnea
  • Current smoking, nicotine, or drug use
  • Nerve or neurologic diseases
  • Cardiovascular, liver, kidney, or respiratory disease
  • Blood pressure 140/90 mmHg or higher
  • Diabetes or polycystic ovarian syndrome
  • Communication barriers
  • Use of prescription medications
  • Malignant cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Duration of each treatment period varies according to crossover design

Participants receive oral propranolol, gemtesa, or placebo and undergo exposure to hypoxia, cold pressor test, and hypercapnia to assess vascular responses.

Multiple visits for each treatment and exposure period

Trial Site Locations

Total: 1 location

1

University of Missouri-Columbia

Columbia, Missouri, United States, 65211

Actively Recruiting

Loading map...

Research Team

J

Jacqueline Limberg

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

3

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here